SCHEMBL1491856

SCHEMBL1491856

COc1ccc(O[C@@H]2O[C@@H](C)[C@H](OCc3ccccc3)[C@H]3OC(C)(C)O[C@@H]23)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LTA4H P09960 1/20 0.35
KCNA5 P22460 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SSTR1 P30872 1/20 0.32
SSTR2 P30874 1/20 0.32
SSTR4 P31391 1/20 0.32
SSTR3 P32745 1/20 0.32
SSTR5 P35346 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ABCB1 P08183 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857852 0.83 LTA4H (0.47) TACR1MEN1KMT2ALTA4HKCNA5
SCHEMBL11886555 0.81 SSTR1 (0.40) TDP1L3MBTL1SSTR1SSTR2SSTR4
SCHEMBL13129875 0.81 PDPK1 (0.37) MEN1KMT2ASSTR1SSTR2SSTR4
SCHEMBL13129819 0.81 PDPK1 (0.37) MEN1KMT2ASSTR1SSTR2SSTR4
SCHEMBL1491873 0.79 SLC5A2 (0.42) TACR1LTA4HSSTR5NPC1RAB9A
SCHEMBL7149762 0.79 SSTR1 (0.42) MEN1KMT2ASSTR1SSTR2SSTR4
SCHEMBL23867745 0.79 BCHE (0.34) MEN1KMT2ASSTR1SSTR2SSTR4
SCHEMBL26759928 0.79 BCHE (0.34) MEN1KMT2ASSTR1SSTR2SSTR4
SCHEMBL7955324 0.78 NT5E (0.43) MEN1KMT2ANPC1RAB9A
SCHEMBL26759922 0.78 MEN1 (0.35) TACR1MEN1KMT2ASSTR1SSTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7901687-B2 Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections ETH ZURICH (CH) 2011-03-08 US disclosed
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections SCHWEIZERISCHES TROPENINSTITUT (CH) 2009-06-18 US disclosed
EP-2012821-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2009-01-14 EP disclosed
WO-2007125089-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections ANTXR2, CERT1, DAD1 TACR1 1907/4885MEN1 1532/4885KMT2A 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.